Amphastar's Naloxone Nasal Spray Delayed; User Human Factors Study Among FDA Concerns

FDA 'complete response' letter follows advisory committee's conclusion that the current naloxone approval standard is inadequate.

FDA entrance sign 2016

FDA declined to approve Amphastar Pharmaceuticals Inc.'s new drug application for a nasal spray formulation of naloxone until the company addresses several issues with the opioid overdose reversal agent.

Amphastar announced on Feb. 21 that it had received a complete response letter (CRL) for its NDA from FDA that...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA

More from Agency Leadership